Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 25–48 of 150
Immortal Dragons is directing capital toward 3D biofabrication technologies that use living cells and biocompatible materials to engineer functional tissues and vascular structures. This represents a strategic shift in longevity investment toward regenerative approaches that intervene before organ failure becomes clinically symptomatic.
Natural killer cells from older adults fail to clear senescent fibroblasts due to overactivation of the Cdc42 protein, which disrupts the cellular machinery required for releasing cytotoxic granules and producing ATP. Pharmacological inhibition of Cdc42 restores this clearing capacity and offers a potential therapeutic target for age-related disease driven by senescent cell accumulation.
Telomir-1 (Telomir-Zn) modulates intracellular metal balance by increasing zinc and reducing iron, influencing epigenetic regulation and cellular stability without triggering cytotoxic stress. This mechanism addresses oxidative stress and genomic integrity pathways implicated in aging and cancer biology.
Clinical evidence shows transplanted stem cells often fail to survive beyond days, yet patients continue improving—suggesting the therapeutic mechanism resides in transient molecular signals rather than cell persistence. This shift from cellular replacement to signal-based regenerative therapy reframes aging as a coordination failure rather than a structural deficit, with profound implications for scalable longevity medicine.
PranaX secured $17 million in Series A funding to develop exosome-based therapeutics licensed from UT MD Anderson, targeting age-related inflammation and tissue degeneration. The company plans to commercialize stem cell-derived exosome products for wellness applications and potentially clinical programs addressing chronic age-related conditions.
Periodic therapeutic phlebotomy restores bone marrow function in aging models, reducing senescence markers and improving tissue integrity across multiple organ systems. The mechanism involves rebalancing hematopoietic homeostasis through rescue of mesenchymal and endothelial stem cells, suggesting a practical intervention with clinical translation potential.
Young muscle-derived stem cells secrete pro-angiogenic and immunomodulatory proteins that decline with age. Systemic transplantation of these young cells into aged mice restored neuromuscular structure and function through paracrine signaling, with effects sustained for two months.
Plasma dilution performed 24 hours after myocardial ischemia–reperfusion injury in aged mice significantly improved cardiac function, reduced fibrosis and inflammation, and restored physical performance through enhanced cellular repair and modified inflammatory signaling pathways. This finding addresses a critical gap in aging-relevant cardiac research by demonstrating that manipulating the blood's humoral environment after acute injury can shift the trajectory of tissue recovery in older organisms.
Pulmatrix and Eos SENOLYTIX are merging to develop PTC-2105, a candidate designed to modulate mitochondrial function and clear senescent cells in sarcopenia and metabolic disease. The transaction signals a fundamental shift in biopharma toward targeting aging biology directly rather than its downstream manifestations.
FGF21 enhances lactate uptake and utilization in the aging brain, protecting against neuroinflammation-driven cognitive decline. This mechanism reveals how metabolic efficiency at the cellular level directly influences neuronal resilience during aging.
Telomerase (TERT) in myeloid cells prevents senescence and pro-inflammatory polarization through mechanisms independent of telomere length. Loss of myeloid TERT drives foam cell formation, dyslipidemia, pulmonary fibrosis, and cardiac dysfunction—establishing TERT as essential for preventing aging-associated multi-organ pathology.
Plasma proteomic analysis of Swiss centenarians identifies a distinct protein signature associated with preserved youthfulness and longevity. This proteomic fingerprint offers a measurable biomarker set for aging trajectories and potential intervention targets.
Phase 1 data for RLS-1496, a GPX4 modulator, demonstrate safety and dose-dependent target engagement alongside reductions in senescence markers and clinical improvement in inflammatory skin conditions. The drug operates through a dual mechanism: clearing senescent cells via ferroptosis while restoring redox balance in stressed neighboring cells, representing a shift toward cellular recalibration rather than indiscriminate senescent cell clearance.
FGF21 activates a cellular repair pathway in spinal disc cells by upregulating SIRT1, which deacetylates FOXO3 and triggers mitochondrial autophagy, thereby suppressing cell senescence and slowing intervertebral disc degeneration. This identifies a targetable molecular axis with direct relevance to preventing age-related spinal structural decline and associated disability.
A February 2026 research roundup covering advances in cellular reprogramming, senolytic effectiveness, immune cell restoration, and cognitive interventions demonstrates multiple convergent pathways for addressing age-related decline. The collective findings suggest that aging is modifiable across multiple biological domains, with implications for clinical translation in vision, neurological, and metabolic disease.
Plasma extracellular vesicles carrying microRNAs show age-specific expression patterns that correlate with biological aging across the human lifespan. These circulating biomarkers may serve as measurable indicators of systemic aging processes and inform stratification of longevity risk.
Cellbricks Therapeutics secured €10 million to advance biofabricated tissue implants toward clinical use, focusing initially on adipose tissue for soft tissue defects and wound healing. The funding supports preclinical validation and manufacturing scale-up for vascularized tissue alternatives to synthetic reconstructive implants.
Garm LLC expanded its non-permanent plasmid gene therapy platform to include Klotho alongside existing follistatin and VEGF therapies, targeting mitochondrial function, inflammation reduction, oxidative stress management, and metabolic aging. The platform operates in Roatan, Honduras, positioning itself as a personalized longevity intervention without permanent genetic modification.
A Phase II clinical trial of XS411, a stem cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease, has advanced based on encouraging Phase I results showing improved motor function and no adverse events. The approach represents a shift from symptomatic management toward cellular repair, potentially restoring function rather than merely masking decline.
Life Biosciences has received FDA clearance to begin the first human trial of cellular reprogramming, testing ER-100 against age-related vision diseases. This represents the first clinical translation of partial reprogramming technology, moving a three-decade research program from laboratory validation into human application.
Lipid mediators in platelet transfusions—particularly lysophosphatidic acid, lysophosphatidylcholine, and sphingosine-1-phosphate—decline with donor age and correlate with adverse transfusion reactions through altered platelet and endothelial cell activation. This finding suggests that donor age-related changes in lipid signaling directly influence transfusion safety and vascular biology.
Unnatural Products raised $45 million to advance macrocyclic peptide therapeutics targeting intracellular protein interactions implicated in cardiometabolic, inflammatory, and age-related diseases. This technology addresses a critical gap in drug development by enabling selective modulation of previously inaccessible cellular pathways.
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
